Stage Migration in Renal Malignancies in COVID Era: A Single-Center Analysis

The COVID - 19 disease, caused by SARS-CoV-2 virus, attained the status of a pandemic by March 2020. There was apprehension among patients suffering from renal malignancies about balancing cancer treatment and preventing COVID-19 infection transmission. We analyzed 184 patients with renal malignancies retrospectively, who presented to our institute over 2 years: 91 patients of renal malignancies in pre-COVID era (March 2019–Feb 2020) and 93 patients in COVID era (March 2020–Feb 2021). The parameters analyzed were age, tumor size, clinical presentation, clinical stage, pathological stage, nuclear grade, and presence of metastasis. Level of significance was kept at 95%, and p value <0.05 was considered significant. The age of patients was comparable in both groups ( p : 0.381). Clinical presentation was also similar in both groups whereas there were more cases diagnosed during routine evaluation in pre-COVID era ( p : 0.022). Tumor size was 5.84 ± 3.03cm vs. 7.10±3.83cm ( p : 0.017) in pre-COVID vs. COVID era, respectively. Patients in COVID era had significantly higher clinical stage ( p = 0.041), pathological stage ( p =0.027), nuclear grade ( p = 0.007), and presence of metastasis ( p = 0.005) as compared to pre-COVID era. Patients, who underwent Nephron-sparing surgery, also had higher pathological stage in COVID era. COVID overshadowed the management of renal malignancies. There was a clear shift and stage migration in patients of renal malignancies in COVID era as compared to pre-COVID era, probably because of less routine health check-ups and patients deferring hospital visits due to fear of contracting COVID infection.